Roche Holding Management
Management criteria checks 2/4
Roche Holding's CEO is Thomas Schinecker, appointed in Mar 2023, has a tenure of 1.67 years. directly owns 0% of the company’s shares, worth €1.02M. The average tenure of the management team and the board of directors is 4.8 years and 7.7 years respectively.
Key information
Thomas Schinecker
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 1.7yrs |
CEO ownership | 0.0004% |
Management average tenure | 4.8yrs |
Board average tenure | 7.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | CHF 11b |
Mar 31 2024 | n/a | n/a | CHF 11b |
Dec 31 2023 | n/a | n/a | CHF 11b |
Sep 30 2023 | n/a | n/a | CHF 11b |
Jun 30 2023 | n/a | n/a | CHF 11b |
Mar 31 2023 | n/a | n/a | CHF 12b |
Dec 31 2022 | CHF 5m | CHF 1m | CHF 12b |
Sep 30 2022 | n/a | n/a | CHF 14b |
Jun 30 2022 | n/a | n/a | CHF 15b |
Mar 31 2022 | n/a | n/a | CHF 14b |
Dec 31 2021 | CHF 4m | CHF 1m | CHF 14b |
Sep 30 2021 | n/a | n/a | CHF 14b |
Jun 30 2021 | n/a | n/a | CHF 14b |
Mar 31 2021 | n/a | n/a | CHF 14b |
Dec 31 2020 | CHF 4m | CHF 879k | CHF 14b |
Sep 30 2020 | n/a | n/a | CHF 14b |
Jun 30 2020 | n/a | n/a | CHF 13b |
Mar 31 2020 | n/a | n/a | CHF 13b |
Dec 31 2019 | CHF 2m | CHF 609k | CHF 13b |
Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Thomas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Thomas Schinecker (49 yo)
1.7yrs
Tenure
CHF 5,335,592
Compensation
Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He serves as Chief Executive Officer at Roche Holding AG since March 15, 2023. He has been Chief Executive Officer...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 11.7yrs | CHF 11.48m | 0.043% € 97.8m | |
Chief Executive Officer | 1.7yrs | CHF 5.34m | 0.00045% € 1.0m | |
Chief Financial & Information Officer | 13.6yrs | CHF 6.05m | 0.0063% € 14.3m | |
Head of Investor Relations | no data | no data | no data | |
General Counsel | 4.6yrs | no data | no data | |
Chief Compliance Officer | 4.8yrs | no data | no data | |
Head of Group Communications | 5.1yrs | no data | no data | |
Chief People Officer | 8.7yrs | CHF 4.25m | 0.0020% € 4.6m | |
Head of Group Media Relations | no data | no data | no data | |
Head of Corporate Business Development | no data | no data | no data | |
Head of Neuroscience Clinical Development | no data | no data | no data | |
Head of Roche Pharma Research & Early Development | 2.7yrs | CHF 82.50k | no data |
4.8yrs
Average Tenure
57yo
Average Age
Experienced Management: RHO6's management team is considered experienced (4.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 11.7yrs | CHF 11.48m | 0.043% € 97.8m | |
Non-Executive Independent Director | 9.8yrs | CHF 330.00k | 0.00013% € 295.6k | |
Director | 1.7yrs | no data | 0.00063% € 1.4m | |
Independent Vice Chairman | 28.8yrs | CHF 402.82k | 3.53% € 8.0b | |
Independent Non Executive Director | 4.7yrs | CHF 360.00k | 0.00025% € 568.5k | |
Non-Executive Independent Director | 9.8yrs | CHF 346.71k | 0% € 0 | |
Non-Executive Independent Director | 7.7yrs | CHF 336.16k | 0.00040% € 909.6k | |
Non-Executive Independent Director | 4.7yrs | CHF 364.59k | no data | |
Director | 1.7yrs | no data | no data | |
Non-Executive Independent Director | 8.7yrs | CHF 367.02k | 0.00034% € 773.1k | |
Independent Non-Executive Director | 2.7yrs | CHF 272.50k | no data |
7.7yrs
Average Tenure
57yo
Average Age
Experienced Board: RHO6's board of directors are considered experienced (7.7 years average tenure).